Posters
(results will display both Free Papers & Poster)
Anterior segment optical coherence tomography(AS-OCT) in intra-corneal foreign bodies
Poster Details
First Author: S.Benbachir MOROCCO
Co Author(s): L. Naoufal M. Firdaoussi A. Bennis F. Chraibi A. Meryem I. Benatiya
Abstract Details
Purpose:
Corneal foreign bodies are reported to be the second most common type of ocular injury.
Anterior segment optical coherence tomography (AS-OCT) is a valuable tool for the early diagnosis and monitoring the progress of treatment in cases of ocular trauma.
The presented case highlights the benefits of AS-OCT for the diagnosis and management of a retained intra-corneal foreign body.
Setting:
This study is made in ophthalmology department at Hassan II university hospital, Fez, Morocco.
Methods:
Case report : A 23 year old male, victim of an eye injury due to a piece of wood projection, presented to the emergency with a red left eye .
Visual acuity of the LE was 20/20. Slit-lamp biomicroscopic examination revealed a peripherally located intracorneal foreign body. Anterior chamber is clear with aqueous humor. Seidel test is negative. The fundus examination was normal.
Results:
AS-OCT showed shadowing of the corneal layers corresponding to the location of the corneal foreign body. A hyper-reflective lesion was observed in anterior corneal stroma, indicating that the foreign body had not completely penetrated the cornea.
The patient was brought into to the operating room and the foreign body was removed via the external route, as it had not completely penetrated the cornea. During the postoperative period he was asymptomatic, although the left eye’s cornea healed with scar tissue.
Conclusions:
The use of AS-OCT allowed to verify and even clarify clinical impression of the intra-corneal foreign bodies. This technology also served as a check on verification of depth and localization of foreign bodies.
AS-OCT findings can also be used to aid in the selection of the most appropriate surgical intervention and to monitor the effects of treatment.
Financial Disclosure:
None